Nibourel O, Guihard S, Roumier C, Pottier Letter, Terre C, Paquet A good, Peyrouze P, Geffroy S, Quentin S, Alberdi A good, Abdelali RB, Renneville A good, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH. Copy-matter investigation known the latest prognostic ;31(3):555-564.
Mohamed In the morning, Balsat Yards, Koering C, Maucort-Boulch D, Boissel Letter, Payen-Homosexual L, Cheok Yards, Mortada H, Auboeuf D, Pinatel C, El-Hamri Yards, Tigaud We, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo Good, Mortreux F, Wattel E. Leuk Res. 2017;-twenty eight.
Mishima Y, Paiva B, Shi J, Playground J, Manier S, Takagi S, Massoud Meters, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro Was, Sacco A beneficial, Capelletti Yards, Detappe A great, Alignani D, Anderson KC, Munshi NC, Do well F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson Virtual assistant, Michor F, San Miguel JF, Ghobrial I will be. 2017;19(1):218-224.
Minnema MC, Kimby Elizabeth, DSa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis Age, Kremer S, Fitsiori Good, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier Meters, Costopoulos Yards, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Tip toward diagnosis, medication and you will effect requirements getting Yahoo-Neel disorder. Haematologica. 2017;102(1):43-51.
Micol JB, Pastore A beneficial, Inoue D, Duployez N, Kim E, Lee South carolina, Durham BH, Chung Year, Cho H, Zhang XJ, Yoshimi An excellent, Krivtsov A, Koche Roentgen, Solary Age, Sinha A, Preudhomme C, Abdel-Wahab O. ASXL2 is important to have haematopoiesis and you can will act as a great haploinsufficient tumour suppressor inside leukemia. Nat Commun. 2017;8:15429.
Mobile Agent
Meunier Yards, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, Wang Y, Faure P, Szymanski G, Duployez N, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Playground S. Activated clean air varieties account manage NF-kappaB activation from the reasonable dose deferasirox in the erythroid progenitors regarding lowest risk myelodysplastic syndromes. Oncotarget. 2017;8(62):105510-105524.
Manier S, Salem KZ, Park J, Landau Da, Getz Grams, Ghobrial Im. Genomic complexity out of numerous myeloma and its logical effects. Nat Rev Clin Oncol. 2017;14(2):100-113.
Manier S, Efforts JT, Sacco Good, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta Meters, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro Are, Daley GQ, Ghobrial I am. The LIN28B/let-eight axis is a novel therapeutic path within the several myeloma. Leukemia. 2017;31(4):853-860.
Manier S, Liu CJ, Avet-Loiseau H, Playground J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco Good, Roccaro Am, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial I am. Prognostic part away from distributing exosomal miRNAs within the several myeloma. Bloodstream. 2017;129(17):2429-2436.
TET2 exon 2 skipping is an independent positive prognostic basis to possess cytogenetically typical acute myelogenous leukemia (AML): TET2 exon dos bypassing for the AML
Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Playground J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown Le, Grey N, Bradner J, Whitesell L, Porco JA, Jr., Ghobrial I will be. Inhibiting the oncogenic interpretation system is an effectual healing means inside the numerous myeloma. Sci Transl Med. 2017;9(389).
Magnez Roentgen, Thiroux B, Taront S, Segaoula Z, Quesnel B, Thuru X. PD-1/PD-L1 joining training using microscale thermophoresis. Sci Representative. 2017;7(1):17623.
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A good, Dumezy F, Feuillard J, Genevieve F, Guerin Elizabeth, Man J, Jouault H, Lepelley P, Maynadie Meters, Solly F, Ballon OW, Preudhomme C, Baruchel An effective, Dombret H, Ifrah Letter, Bene MC. Prognostic property value multicenter bristlr move cytometry matched up comparison out-of restricted recurring condition inside intense myeloblastic leukemia. Hematol Oncol. 2017.